Life Sciences Tools and Services(IN00319.US)

Danaher: Solid Core Performance and Bioprocessing Upside Support Buy Rating into 2026

Danaher has received a Buy rating from Jefferies analyst Tycho Peterson, who set a price target of $265.00. The positive outlook is based on solid fourth-quarter results, particularly in bioprocessing and diagnostics. Management's guidance for mid-single-digit core growth and high-single-digit EPS expansion is deemed achievable. Key growth drivers include stabilizing demand in bioprocessing and potential recovery in life sciences spending. Peterson's analysis suggests that these factors, along with a favorable M&A environment, support the Buy recommendation for Danaher.

14:42 ET Kuehn Law Encourages Investors of Avantor, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Avantor, Inc. (NYSE: AVTR). A federal securities lawsuit alleges that insiders misrepresented the company's competitive position and failed to disclose negative impacts from increased competition. Shareholders who purchased AVTR before March 5, 2024, are encouraged to contact Kuehn Law for potential legal action, as there may be limited time to enforce their rights. Kuehn Law covers all case costs for clients.

Danaher shares are trading lower. The company reported Q4 financial results and issued FY26 guidance.

Madame Bioscience Appoints Ingfa Petvipusit As CEO

Jan 28 (Reuters) - Madame Bioscience PCL (MADAME.BK) :* APPOINTS INGFA PETVIPUSIT AS CEO Further company coverage: (MADAME.BK)

Atlantic International Acquires Circle8 Group in $1.2 Billion Workforce Platform Deal

Atlantic International Corp. has acquired Circle8 Group for $1.2 billion, creating a global workforce solutions platform with $1.2 billion in annual revenue. This acquisition expands Atlantic's operations into Europe and enhances its IT staffing capabilities. Circle8, which generated $780 million in revenue in 2025, is expected to reach $1 billion in 2026. Circle8 will operate as a subsidiary, with founder Guus Franke joining Atlantic's Board as Executive Chairman while remaining CEO of Circle8. The merger aims to leverage geographic reach and cross-selling opportunities.